XML 73 R60.htm IDEA: XBRL DOCUMENT v3.24.0.1
License Agreements - MorphoSys (Details)
$ in Thousands
1 Months Ended 12 Months Ended 48 Months Ended
Jan. 31, 2020
Dec. 31, 2023
USD ($)
shares
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2023
USD ($)
shares
Dec. 31, 2020
USD ($)
License agreements            
Long term investments   $ 187,716 $ 133,676   $ 187,716  
Unrealized gain (loss) on long term investments   43,893 (87,590) $ (24,072)    
Research and development   $ 1,627,594 1,585,936 1,458,179    
MorphoSys AG            
License agreements            
Investment owned (in shares) | shares   3,600,000     3,600,000  
ADSs            
License agreements            
Conversion ratio   0.25     0.25  
MorphoSys AG            
License agreements            
Long term investments   $ 35,900 13,000   $ 35,900  
Unrealized gain (loss) on long term investments   $ 22,900 $ (21,200) (68,700)    
Profit (loss) sharing ratio   50.00% 50.00%      
Research and development   $ 76,100 $ 99,700 77,000    
Accrued and other liabilities   18,800 28,500   18,800  
MorphoSys AG | Tafasitamab Product and Service | United States            
License agreements            
(Profit) and loss sharing under collaboration agreements   $ 2,000 $ 8,000 $ 37,000    
MorphoSys AG | Development and Regulatory Milestones            
License agreements            
Milestone payment made under license agreement         $ 2,500  
MorphoSys AG | Development and Regulatory Milestones | Maximum            
License agreements            
Additional milestone payments under the license agreement           $ 737,500
MorphoSys AG | Commercialization Milestones | Maximum            
License agreements            
Additional milestone payments under the license agreement           $ 315,000
MorphoSys AG | MorphoSys AG            
License agreements            
Funding of future development costs 45.00%          
MorphoSys AG | Incyte            
License agreements            
Funding of future development costs 55.00%